

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel in the order listed for Form Page 2.
Follow the sample format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Haynes, Johnson Jr.		Professor, Internal Medicine	
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
Tuskegee University, Tuskegee, AL	B.S.	1975	Biology
University of South Alabama Medical School	M.D.	1975-1980	MD
University of South Alabama Medical School	Res/Chief Res/Fellow	1980-1986	Int Med/Pulmonary
University of Colorado Health Science Center	Research Fellowship	1986-1988	Pulmonary Vascular

PROFESSIONALEXPERIENCE:**E**

1988-1992 Assistant Professor, Department of Medicine, University of South Alabama College of Medicine (USACOM), Mobile, AL
 1992-1995 Associate Professor, Department of Medicine, USACOM, Mobile, AL.
 1993-pres Associate Professor of Physiology, USACOM, Mobile, AL.
 1995-pres. Professor, Department of Medicine, USACOM, Mobile, AL.
 1999-pres. Adjunct Professor of Medicine, Department of Physician Assistant Studies, USACOM, Mobile, AL.
 1993-pres. Director, Adult Clinical Programs, USA Comprehensive Sickle Cell Center, Mobile, AL.
 2001-pres. Director, USA Comprehensive Sickle Cell Center, Mobile, AL.

HONORS:

Alpha Kappa Mu Honor Society (1974)
 Who's Who in American Colleges and Universities (1975)
 Victor Benator Award for Teaching Excellence (1983)
 American Lung Associate Fellowship Recipient (1983-1986)
 National Research Service Award (1986-1988)
 Fellow, American College of Chest Physicians (1990)
 Alpha Omega Alpha Honor Medical Society (1991)
 Fellow, American College of Physicians (1991)
 Who's Who in American Thoracic Society (1999)
 America's Top Doctors (2001,2002)

SELECTED PUBLICATIONS:

Haynes J, Allison R. Pulmonary Edema: A complication of the management of sickle cell disease crises. *Am.J.Med* 80:833-840, 1986.
 Haynes J, Seibert A, Bass J, and Taylor A. U74500A inhibition of oxidant lung injury. *Am.J.Physiol.* 259:H144-H148, 1990.
 Haynes J, Seibert A, Shah A, and Taylor A. Normal vs sickle red blood cells: Hemodynamic and permeability characteristics in reperfusion injury. *JAAMP* 1(3):62-66, 1990.
 Kirkpatrick MD, Haynes J, and Bass J. Results of bronchoscopically-obtained lower airway cultures from adult sickle cell disease patients with acute chest syndrome. *Am.J.Med.* 90:206-210, 1991.
 Seibert A, Taylor AE, Bass J, and Haynes J. Hemoglobin potentiates oxidant lung injury in isolated rat lungs. *Am.J.Physiol.* 260(29):H1980-H1984, 1991.
 Haynes J, Taylor AE, Dixon D, and Voelkel N. Microvascular hemodynamics in the sickle red blood cell perfused isolated rat lung. *Am.J.Physiol.* 264(33):H484-H489, 1993.
 Haynes J and Bass J. Sickle cell lung disease. *Pulmonary Critical Care Update*, Lesson 20, Volume 8, 1993.

SELECTED PUBLICATIONS (continued):

- Haynes J and Kirkpatrick M. The acute chest syndrome of sickle cell disease. *Am.J.Med.Sci.* 305(5):326-330, 1993.
- Kirkpatrick MD and Haynes J. Sickle cell disease and the pulmonary circulation. *Seminars in Respir. Crit. Care Med.* 15(6):473-481, 1994.
- Haynes J, Obiako B, Babal P, and Stevens T. 5'-N-ethylcarboxamide)-adenosine desensitizes the A2 adenosine receptor in lung circulation. *Am.J.Physiol.* 276(45):H1877-H1883, 1999.
- Culberson D, Mancini EA, Shah AK, Haynes J, Ballas SK, Pegelow C, and Vichinsky E. Nesidioblastosis in sickle cell disease. *Ped.Pathol.Mol.Med.* 20(2):155-165, 2001.
- Pack-Mabien A, Labbe E, Herbert D, and Haynes J. Nurses' attitudes and practices in sickle cell pain management. *Applied Nursing Res* 14(4):187-192, 2001.
- Haynes J and Obiako B. Activated polymorphonuclear cells increase sickle red blood cell retention in lung: Role of phospholipids. *Am.J.Physiol.* 282:H122-H130, 2002.

SELECTED ABSTRACTS:

- Haynes J and Obiako B. Platelet activated factor with leukotriene B4 enhance sickle red blood cell (SRBC) retention in the lung circulation. 23rd National Sickle Cell Program Meeting, Washington, DC, 1999.
- Pack-Mabien A, Labbe E, Herbert D, and Haynes J. Nurses' attitudes and practices in sickle cell pain management. 23rd National Sickle Cell Program Meeting, Washington, DC, 1999.
- Haynes J and Obiako B. WEB 2170 and zileuton inhibit enhanced sickle red blood cell (SRBC) retention mediated by the activated polymorphonuclear cell (A-PMN) in the lung circulation. 24th National Sickle Cell Program Meeting, Philadelphia, PA, 2000.
- Dixon B, Pace B, Obiako B, and Haynes J. Zileuton: A potential new treatment approach for acute chest syndrome (ACS). *Blood* 96(11):A29, 2000.
- Haynes J and Obiako B. WEB 2170: A potential new treatment approach for acute chest syndrome (ACS). *Am.J.Respir.Crit.Care Med.* 163(5):A124, 2001.
- Haynes J, Baliga BS, Dixon B, Obiako B and Pace B. Zileuton: An inhibitor of activated polymorphonuclear cell mediated sickle erythrocyte retention in lung and promoter of hemoglobin F induction *in vitro*. 25th National Sickle Cell Program Meeting, New York, NY, Abst. #91.
- Wu SW, Haynes J, Obiako B, Ming L, Stevens T. T-type Ca²⁺ channel activation contributes to vaso-occlusion of sickled erythrocytes in infamed lung. *FASEB J.* 16:A407, 2002.
- Morales RE, Babal P, Khimenko PL, Stevens T, Obiako B and Haynes J. A2 adenosine receptor (A2AR) distribution in the rat pulmonary circulation. *Am J Respir and Crit Care Med* 165(8): A336, 2002.
- Baliga BS, Obiako B, and Haynes J. Reversal of zileuton inhibition of BFU-E colonies and fetal hemoglobin expression by L-arginine. 26th National Sickle Cell Program Meeting, Washington DC, September, 2002.
- Haynes J, Hester R, and Obiako B. Hydroxyurea decreases sickle erythrocyte retention/adherence in the pulmonary circulation. 26th National Sickle Cell Program Meeting, Washington, DC, September, 2002.
- Haynes J, Cummings J, Pack-Mabien A, and Boullier J. Voiding dysfunction in women with sickle cell anemia. 26th National Sickle Cell Program Meeting, Washington DC, September, 2002.

BOOK CHAPTERS:

- Haynes J. Acute localized pulmonary infiltrate. In: Schwarz MI (ed): *Pulmonary Grand Rounds*. B.C. Decker, Inc., 1990.
- Taylor AE, Barnard JW, Seibert AF, and Haynes J. Models of tissue injury in critical care research. In: *Critical Care State of the Art: Society of Critical Care Medicine* 13:129-131, 1992.
- Taylor AE, Seibert A, Haynes J, Bernard J, and Wilson P. Increased lymph flow associated with damaged capillary endothelium. In: *Progress in Lymphology-XIII. Proceedings of the XII International Congress of Lymphology*. Edited by RV Cluzan, AP Pecking and FM Lokiec. Exerta Medica, 1992.
- Haynes J, Mancini E, Voelkel N. The Lung in Sickle Cell Disease. In: *The Sickle Hemoglobinopathies Science and Medicine*. Edited by SH Embry, RP Hebbel, M Mohandas, and M Steinberg. Raven Press, 1994.
- Haynes J and Obiako B. Phospholipid Products from Activated Polymorphonuclear Cells: Potential Role in Sickle Red Blood Cell Microvascular Occlusion. In: *Sickle Cell Disease and Endothelial Biology*. AHA Monograph. EK Weir, HL Reeve, JT Reeves (eds)., Futura Publishing Co., Inc., 2002.

OTHER SUPPORT:

ACTIVE:

2P60 HL 38639		
NIH/NHLBI	4/01/98-3/31/03	25%
	\$424,727	

Comprehensive Sickle Cell Program: "Acute Lung Injury in Sickle Cell Disease"

The major goal of this project is to elucidate the role(s) of sickle red blood cells (SRBC)-endothelial cell (EC)-polymorphonuclear cell (PMN) interactions in sickle cell related acute lung injury.

2P60 HL 38639		
NIH/NHLBI	4/01/98-3/31/03	26.4%
	\$379,585	

Comprehensive Sickle Cell Program: "Medical Education of Health Professionals"

The major goal of this project is to improve the health care of sickle cell patients through programs which expedite the transfer of knowledge and technology related to sickle cell disease to health care providers.

2P60 HL 38639		
NIH/NHLBI	4/01/98-3/31/03	20%
	\$1,201,273	

Comprehensive Sickle Cell Program: "Administrative Core"

The major goal of this project is the oversight of all aspects of the USA Comprehensive Sickle Cell Center including research, clinical care, community programs, diagnostic program, and educational programs.